Premature mortality and years of potential productive life lost due to HPV-attributable cancers in Brazil and Mexico: 2011 Versus 2023 Authors: Paula Cristina Pungartnik, Cintia Irene Parellada, Daniela Mayumi Usuda Prado Rocha, Rodrigo Gonçalves Queijo, Ana Luiza Bierrenbach, Juan Carlos Orengo Published: 2026 ABSTRACT ABSTRACTHuman papillomavirus (HPV) remains a preventable cause of cancer mortality in Latin America. Using 2011 and 2023 mortality data from Brazil and Mexico, we estimated HPV-attributable cancer deaths, years of life lost (YLL), average YLL, and years of potential productive life lost (YPPLL) by sex, age, and cancer type, applying attributable fractions. WHO life tables were used in sensitivity analyses. HPV‑attributable deaths were higher in 2023 than in 2011, increasing from 6,515 to 9,533 in Brazil (YLL +44.6%) and from 4,303 to 4,997 in Mexico (YLL +21.4%). These absolute differences were consistent with demographic change, while age-standardized mortality rates changed more modestly. Cervical cancer dominated the burden in both countries. Among men, oropharyngeal YLL was 33.5% and 74.6% higher in Brazil and Mexico in 2023 relative to 2011; the corresponding differences for penile cancer were 54.8% and 37.7%, respectively. Anal cancer YLL showed the largest relative differences in Brazil (+159.1% in women; +203.8% in men), whereas Mexico showed a smaller difference (+32.8% in men). Although deaths were concentrated at ≥60y, substantial YLL and YPPLL occurred at younger age groups. In 2023, YPPLL totaled 97,404 y in Brazil and 51,735 y in Mexico, 43.9% and 26.7% higher than in 2011, respectively. WHO‑based sensitivity analyses yielded higher absolute YLL estimates but preserved relative patterns. These findings reveal a persistent and preventable burden of premature mortality and YPPLL from HPV‑attributable cancers in Brazil and Mexico, underscoring the need for expanded HPV vaccination, screening, timely diagnosis, and equitable treatment across affected cancer sites. Introduction Human papillomavirus (HPV) is responsible for virtually all cervical cancers and a substantial proportion of other anogenital and head and neck cancers in both sexes.1 In 2022, an estimated 422,935 deaths worldwide were attributable to HPV, representing 4.5% of all cancer deaths.2 This burden is not evenly distributed: the majority of HPV-attributable deaths occur in low- and middle-income countries, reflecting persistent gaps in access to screening, vaccination, and timely treatment.3,4 These inequities are particularly evident in Latin America and the Caribbean, where HPV-attributable cancers accounted for 62,809 deaths in 2022, representing approximately 8% of all cancer deaths and placing the region among those with the highest global burden.2,3,5,6 While cervical cancer contributes the largest share of mortality, HPV-attributable deaths among men, primarily from anal, penile, and head and neck cancers, are substantial and remain under-recognized in the region.2,7,8 Importantly, mortality counts alone underestimate the broader societal burden of HPV‑attributable cancers. Summary measures such as years of life lost (YLL), average YLL (AYLL), and years of potential productive life lost (YPPLL) provide a more comprehensive assessment of disease burden by capturing premature mortality, the average lifespan reduction per death, and the loss of potential productive years due to deaths occurring during working ages.9,10 In high-income settings, these indicators have revealed a substantial burden. In 2017, HPV-attributable deaths in the United States resulted in 154,954 YLL, driven by cervical cancer in women and anal and oropharyngeal cancers in men.11 In Europe, women with cervical cancer had an AYLL of 25 y, while men with head and neck cancers lost up to 27 y.12 Despite the high mortality burden in Latin America and the Caribbean,13 estimates of premature mortality and YPPLL attributable to HPV remain scarce. Brazil and Mexico together contribute substantially to the regional burden of HPV-attributable cancer deaths, making them critical settings for addressing this evidence gap.5 In both countries, HPV vaccination has been incorporated into national immunization programs (NIP). In Mexico, the program was initially introduced in 2008 for girls aged 9–12 y and expanded to boys in 2025.14–16 In Brazil, vaccination targeting girls aged 9–14 y began in 2014, with boys incorporated into the program in 2017.15,17 Given the timing of NIP implementation, cohort eligibility, and the natural history of HPV-related diseases, measurable reductions in cancer incidence and mortality are expected only after vaccinated cohorts reach the ages at which these outcomes typically occur. Estimating premature mortality and YPPLL in 2011 and 2023 provides evidence on the magnitude and distribution of HPV‑attributable cancer burden in Brazil and Mexico. These estimates provide a baseline for future monitoring of HPV-attributable cancer burden and may help contextualize the potential impact of prevention and control strategies, including vaccination, screening, and timely treatment. In this study, we estimated YLL, AYLL, and YPPLL due to HPV-attributable cancers in Brazil and Mexico in 2011 and 2023, stratified by sex, cancer type, and age group. We additionally assessed crude and age‑standardized mortality rates to contextualize differences in absolute burden between the two study years in relation to underlying mortality risk. Material and methods Study design This retrospective observational study estimated the burden of HPV-attributable cancers in Brazil and Mexico in 2011 and 2023 using secondary data from national mortality databases. Study population and definitions The study population included all registered deaths in 2011 and 2023 in Brazil and Mexico for which the underlying cause of death corresponded to one of eight HPV-associated cancers: cervical, vaginal, vulvar, penile, anal, oropharyngeal, laryngeal, and oral cavity cancers. Causes of death were identified using International Classification of Diseases, 10th Revision (ICD-10) codes (Supplementary Table S1). HPV‑associated cancers were defined as all cancers occurring at anatomical sites for which HPV infection is a recognized causal factor, irrespective of the HPV status of individual tumors. Working age was defined as 15–64 y, reflecting typical labor force entry and statutory retirement ages in Brazil and Mexico.18–21 Data sources Mortality data for HPV-associated cancers were sourced from the national mortality databases: Sistema de Informação sobre Mortalidade (SIM) in Brazil and the Estadísticas de Defunciones Registradas of the Instituto Nacional de Estadística y Geografía (INEGI) in Mexico.22,23 Both databases are publicly available, contain de-identified data coded according to ICD-10, and capture registered deaths in their respective countries. Both countries’ death-registration data were classified as high quality in the World Health Organization (WHO) assessment.24 For Brazil, life tables and population projections were obtained from the Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística – IBGE).25 For Mexico, where official complete life tables were not available, population projections were sourced from the National Population Council (Consejo Nacional de Población – CONAPO).26 Statistical analysis Primary outcomes included the number of HPV-attributable cancer deaths, YLL, AYLL, YPPLL, and percentage change in these indicators between 2011 and 2023. Analyses were stratified by country, sex, age group, and cancer type. Head and neck cancers were analyzed both by individual anatomical sites (oropharyngeal, laryngeal, and oral cavity cancers) and as an aggregated category. Age at death was summarized using the median and interquartile range (25th–75th percentile). Because national mortality databases report deaths at HPV-associated cancer sites, site-specific attributable fractions (AFs) were applied to these deaths to estimate HPV-attributable deaths for each cancer site. AFs reflect the proportion of cancers causally attributable to HPV infection at each anatomical site and are widely used when individual tumor HPV status is unavailable. AFs were derived from published studies, prioritizing studies with large samples or country-specific or regional estimates from Brazil, Mexico, or Latin America, when available (Supplementary Table S2).5,27–29 For cancers with well-established HPV attribution, we applied published global AFs.5,28 AFs were 100% for cervical and anal cancers, 78% for vaginal cancer, and 51% for penile cancer, based on published global estimates.5,28 For vulvar cancer, age-specific AFs were applied (<60 y: 48%; ≥60 y: 15%) to reflect the lower HPV-attributable fraction at older ages.5 For head and neck sites, AFs were derived from HPV DNA/p16INK4a-based studies from Latin American populations. For Brazil, AFs were calculated using pooled Latin American/South American data: 21.2% for oropharyngeal cancer, 6.3% for oral cavity cancer, and 4.5% for laryngeal cancer.27 For Mexico, AFs were 39.2% for oropharyngeal cancer, 14.7% for laryngeal cancer, and 9.6% for oral cavity cancer (Supplementary Table S2).29 The same AFs were applied to both study years because individual-level tumor HPV status was unavailable in the national mortality databases. HPV-attributable cancer deaths were estimated using the formula:(1)HPV−attributable deathsijt=Deathsijt∗AFi where i refers to each HPV-associated cancer type, j to sex, and t to year. YLL were estimated by multiplying HPV-attributable deaths by the remaining life expectancy at the age of death for each cancer type and by sex, using the following formula:(2)HPV−attributable YLLijt=Deathsijt∗AFi⋅LEj,age where LE (j, age) is the remaining life expectancy at the age of death for sex j. Life expectancy at the age of death was derived from national life tables for 2023 and applied uniformly to deaths in both study years, ensuring that YLL estimates were calculated using a common life expectancy reference. For Brazil, sex-specific life tables were obtained from the IBGE.25 For Mexico, complete life tables were constructed using the method of Fergany (1971),30 based on INEGI mortality data23 and CONAPO population projections.26 Abridged tables were interpolated to single-year age intervals using cubic B-splines with knots at ages 1, 5, 20, and 60 y, implemented with the splines package in R. Life expectancy at birth in 2023 was 73.1 for males and 79.7 for females in Brazil, and 73.1 for males and 78.8 for females in Mexico (Supplementary Table S3). AYLL was calculated to assess the average lifespan reduction per HPV-attributable cancer death. It was computed using the following formula:(3)HPV−attributable AYLLijt=HPV−attributable YLLijtHPV−attributable deathsijt where i refers to each HPV-associated cancer type, j to sex, and t to year. YPPLL was estimated to quantify the potential loss of productive life associated with premature mortality in the working-age population, based on age at death and a working-age cutoff. Deaths occurring outside the defined working age range (i.e., under 15 and aged 65 or older) were assigned a YPPLL of zero. For eligible cases, YPPLL was calculated using the formula:(4)HPV−attributable YPPLLijt=Deathsi,j,t∗AFi∗65−age at death where i refers to each HPV-associated cancer type, j to sex, and t to year. Percentage change in burden between 2011 and 2023 was calculated for both YLL and YPPLL using the following formula (YLL is shown as an example):(5)%HPV−attributableijt=HPV−attributable YLLij2023−HPV−attributable YLLij2011HPV−attributable YLLij2011∗100 where YLLi, j, 2011 and YLLi, j, 2023 denote YLL for cancer type i and sex j in 2011 and 2023, respectively. Mortality rate analysis To contextualize differences in YLL, AYLL, and YPPLL between 2011 and 2023, we computed crude mortality rates (CMRs) and age‑standardized mortality rates (ASMRs) per 100,000 population by country, sex, and cancer site. ASMRs were calculated by direct standardization using the WHO World Standard Population 2000–2025.31 Population denominators were obtained from IBGE for Brazil and CONAPO for Mexico.25,26 Sensitivity analysis To assess international comparability, YLL were also estimated using the WHO Global Health Estimates (GHE) standard life tables.32 While national life tables were used in the primary scenario to reflect local mortality patterns, WHO life tables provided a standardized benchmark for cross-country comparison. Because the WHO GHE life tables are abridged, they were converted into complete life tables using the same cubic B-spline interpolation method applied to the Mexican life tables constructed for this study (Supplementary Table S3). Results Brazil Across both sexes in Brazil, the absolute number of HPV-attributable cancer deaths increased from 6,515 in 2011 to 9,533 in 2023, with total YLL rising from 169,946 to 245,770 (+44.6%) (Table 1; Supplementary Table S4).Table 1.Life-table based years of life lost and years of potential productive life lost due to HPV-attributable cancers in Brazil, by cancer type and sex, 2011 and 2023. 20112023Δ% (2011–2023)Cancer typeDeathsAge at deathYLLYPPLLDeathsAge at deathYLLYPPLLYLLYPPLLn (%)median (P25-P75)years (%)years (%)n (%)median (P25-P75)years (%)years (%)%%Female Anal179 (3.2)66 (56–77)3,629 (2.4)932 (1.5)476 (5.9)68 (56–76)9,402 (4.3)2,346 (2.6)159.1151.7Cervical5,160 (91.6)56 (45–69)142,369 (93.8)58,707 (95.9)7,209 (89.2)56 (44–69)201,319 (92.2)84,856 (95.2)41.444.5Laryngeal24 (0.4)66 (57–76)465 (0.3)110 (0.2)27 (0.3)68 (60–78)514 (0.2)100 (0.1)10.5−9.1Oral cavity23 (0.4)74 (62–83)390 (0.3)77 (0.1)29 (0.4)73 (60–83)502 (0.2)113 (0.1)28.746.8Oropharyngeal80 (1.4)67 (54–78)1,641 (1.1)446 (0.7)121 (1.5)67 (58–76)2,385 (1.1)564 (0.6)45.326.5Vaginal93 (1.7)69 (59–82)1,699 (1.1)429 (0.7)111 (1.4)73 (60–81)2,003 (0.9)518 (0.6)17.920.7Vulvar72 (1.3)73 (62–83)1,578 (1.0)537 (0.9)106 (1.3)75 (65–83)2,166 (1.0)675 (0.8)37.325.7Head and neck127 (2.3)68 (57–79)2,496 (1.6)633 (1.0)177 (2.2)69 (59–79)3,401 (1.6)777 (0.9)36.322.7Overall HPV-attributable5,631 (100.0)60 (48–72)151,771 (100.0)61,238 (100.0)8,079 (100.0)60 (47–73)218,291 (100.0)89,172 (100.0)43.845.6MaleAnal102 (11.5)62 (50–74)2,150 (11.8)887 (13.7)344 (23.7)65 (55–75)6,532 (23.8)2,116 (25.7)203.8138.6Laryngeal151 (17.1)62 (54–71)2,951 (16.2)901 (13.9)182 (12.5)66 (59–73)3,155 (11.5)721 (8.8)6.9−20.0Oral cavity61 (6.9)61 (52–70)1,257 (6.9)439 (6.8)73 (5.0)65 (57–72)1,340 (4.9)368 (4.5)6.6−16.2Oropharyngeal401 (45.4)59 (52–67)8,645 (47.6)3,091 (47.8)588 (40.4)62 (55–69)11,543 (42.0)3,395 (41.2)33.59.8Penile169 (19.1)66 (53–77)3,172 (17.5)1,147 (17.7)267 (18.4)66 (55–76)4,909 (17.9)1,632 (19.8)54.842.3Head and neck613 (69.3)61 (53–70)12,853 (70.7)4,431 (68.5)843 (58.0)64 (57–72)16,038 (58.4)4,484 (54.5)24.81.2Overall HPV-attributable884 (100.0)61 (53–70)18,175 (100.0)6,465 (100.0)1,454 (100.0)64 (57–72)27,479 (100.0)8,232 (100.0)51.227.3Both sexesOverall HPV-attributable6,515 (100.0)60 (51–71)169,946 (100.0)67,703 (100.0)9,533 (100.0)63 (52–72)245,770 (100.0)97,404 (100.0)44.643.9HPV, human papillomavirus; YLL, years of life lost; YPPLL, years of potential productive life lost. Head and neck cancers represent the aggregate of oral cavity, laryngeal, and oropharyngeal cancers and are not an additional mutually exclusive category. Δ%: percentage change from 2011 to 2023, calculated as [(2023 value − 2011 value) / 2011 value] × 100. HPV-attributable deaths were estimated by applying site-specific attributable fractions to total deaths and rounding to the nearest whole number (≥0.5, rounded up; <0.5, rounded down). Table 1.Life-table based years of life lost and years of potential productive life lost due to HPV-attributable cancers in Brazil, by cancer type and sex, 2011 and 2023. 20112023Δ% (2011–2023)Cancer typeDeathsAge at deathYLLYPPLLDeathsAge at deathYLLYPPLLYLLYPPLLn (%)median (P25-P75)years (%)years (%)n (%)median (P25-P75)years (%)years (%)%%Female Anal179 (3.2)66 (56–77)3,629 (2.4)932 (1.5)476 (5.9)68 (56–76)9,402 (4.3)2,346 (2.6)159.1151.7Cervical5,160 (91.6)56 (45–69)142,369 (93.8)58,707 (95.9)7,209 (89.2)56 (44–69)201,319 (92.2)84,856 (95.2)41.444.5Laryngeal24 (0.4)66 (57–76)465 (0.3)110 (0.2)27 (0.3)68 (60–78)514 (0.2)100 (0.1)10.5−9.1Oral cavity23 (0.4)74 (62–83)390 (0.3)77 (0.1)29 (0.4)73 (60–83)502 (0.2)113 (0.1)28.746.8Oropharyngeal80 (1.4)67 (54–78)1,641 (1.1)446 (0.7)121 (1.5)67 (58–76)2,385 (1.1)564 (0.6)45.326.5Vaginal93 (1.7)69 (59–82)1,699 (1.1)429 (0.7)111 (1.4)73 (60–81)2,003 (0.9)518 (0.6)17.920.7Vulvar72 (1.3)73 (62–83)1,578 (1.0)537 (0.9)106 (1.3)75 (65–83)2,166 (1.0)675 (0.8)37.325.7Head and neck127 (2.3)68 (57–79)2,496 (1.6)633 (1.0)177 (2.2)69 (59–79)3,401 (1.6)777 (0.9)36.322.7Overall HPV-attributable5,631 (100.0)60 (48–72)151,771 (100.0)61,238 (100.0)8,079 (100.0)60 (47–73)218,291 (100.0)89,172 (100.0)43.845.6MaleAnal102 (11.5)62 (50–74)2,150 (11.8)887 (13.7)344 (23.7)65 (55–75)6,532 (23.8)2,116 (25.7)203.8138.6Laryngeal151 (17.1)62 (54–71)2,951 (16.2)901 (13.9)182 (12.5)66 (59–73)3,155 (11.5)721 (8.8)6.9−20.0Oral cavity61 (6.9)61 (52–70)1,257 (6.9)439 (6.8)73 (5.0)65 (57–72)1,340 (4.9)368 (4.5)6.6−16.2Oropharyngeal401 (45.4)59 (52–67)8,645 (47.6)3,091 (47.8)588 (40.4)62 (55–69)11,543 (42.0)3,395 (41.2)33.59.8Penile169 (19.1)66 (53–77)3,172 (17.5)1,147 (17.7)267 (18.4)66 (55–76)4,909 (17.9)1,632 (19.8)54.842.3Head and neck613 (69.3)61 (53–70)12,853 (70.7)4,431 (68.5)843 (58.0)64 (57–72)16,038 (58.4)4,484 (54.5)24.81.2Overall HPV-attributable884 (100.0)61 (53–70)18,175 (100.0)6,465 (100.0)1,454 (100.0)64 (57–72)27,479 (100.0)8,232 (100.0)51.227.3Both sexesOverall HPV-attributable6,515 (100.0)60 (51–71)169,946 (100.0)67,703 (100.0)9,533 (100.0)63 (52–72)245,770 (100.0)97,404 (100.0)44.643.9HPV, human papillomavirus; YLL, years of life lost; YPPLL, years of potential productive life lost. Head and neck cancers represent the aggregate of oral cavity, laryngeal, and oropharyngeal cancers and are not an additional mutually exclusive category. Δ%: percentage change from 2011 to 2023, calculated as [(2023 value − 2011 value) / 2011 value] × 100. HPV-attributable deaths were estimated by applying site-specific attributable fractions to total deaths and rounding to the nearest whole number (≥0.5, rounded up; <0.5, rounded down). Life-table based years of life lost and years of potential productive life lost due to HPV-attributable cancers in Brazil, by cancer type and sex, 2011 and 2023. HPV, human papillomavirus; YLL, years of life lost; YPPLL, years of potential productive life lost. Head and neck cancers represent the aggregate of oral cavity, laryngeal, and oropharyngeal cancers and are not an additional mutually exclusive category. Δ%: percentage change from 2011 to 2023, calculated as [(2023 value − 2011 value) / 2011 value] × 100. HPV-attributable deaths were estimated by applying site-specific attributable fractions to total deaths and rounding to the nearest whole number (≥0.5, rounded up; <0.5, rounded down). Among women, HPV-attributable deaths increased from 5,631 in 2011 to 8,079 in 2023, accompanied by a 43.8% increase in YLL (Table 1). Cervical cancer represented 91.6% of deaths and 93.8% of YLL in 2011 and 89.2% of deaths and 92.2% of YLL in 2023 (Table 1; Figure 1(A)). Among non-cervical cancers in women, the largest increase in YLL was observed for anal cancer (+159.1%), followed by oropharyngeal (+45.3%), vulvar (+37.3%), oral cavity (+28.7%), and vaginal cancer (+17.9%), whereas laryngeal cancer showed a modest increase (+10.5%) (Figure 2(A)). Figure 1.Distribution of HPV-attributable years of life lost (YLL), by cancer type and sex, in Brazil (A, B) and Mexico (C, D), 2011 and 2023.The figure consists of four horizontal bar charts showing the distribution of HPV-attributable years of life lost (YLL) by cancer type in Brazil and Mexico in 2011 and 2023. The x-axisshows the percentage contribution of each type of cancer to total YLL (0% to 100%), while the y-axis lists the cancer types included in the analysis. Numbers adjacents to the bars indicate absolute YLL values, whereas bar lenghts represent the proportional distribution of TLL. The cancers types shown include: All HPV-attributable, Cervical, Anal, Oropharyngeal, Vaginal, Vulvar, Laryngeal, Oral cavity. The image A shows a grouped horizontal bar chart titled, Brazil-Females. Cervical cancer represented the largest proportion of HPV-attributable YLL in both 2011 and 2023, accounting for more than 90% of total YLL. The proportional contribution of anal cancer increased in 2023 compared to 2011. The image B shows a grouped horizontal bar chart titled, Brazil-Males. YLL was predominantly attributable to Oropharyngeal cancer in both years, followed by Penile, Laryngeal, Anal, Oral cavity cancers. The proportional contribution of anal cancer increased in 2023, while laryngeal and oral cavity cancers contributed smaller proportions. Image C shows a grouped horizontal bar chart titled, Mexico-Females. Cervical cancer accounted for nearly all female HPV-attributable YLL in both years, with Anal, Vaginal, Vulvar, Laryngeal, Oropharyngeal, Oral cavity contributing smaller proportions. The image D shows a grouped horizontal bar chart titled, Mexico-Males. Penile cancer was the largest contributor to YLL in both years. The contribution of Oropharyngeal cancer increased in 2023, whereas Laryngeal cancer decreased. Anal and oral cavity cancers represented smaller proportions of total YLL.HPV-related years of life lost by cancer type and sex in Brazil and Mexico, shown as horizontal bar charts.Note: (A) Brazil – females; (B) Brazil – males; (C) Mexico – females; (D) Mexico – males.HPV, human papillomavirus; YLL, years of life lost.Numbers adjacent to the bars correspond to the absolute YLL for each cancer type, whereas bar lengths represent the proportional distribution of YLL (%). HPV‑attributable outcomes were derived by applying site‑specific attributable fractions to deaths at HPV‑associated cancer sites. Figure 2.Percentage change in years of life lost (YLL) and years of potential productive life lost (YPPLL) due to HPV-attributable cancers using national life tables, by cancer type and sex, in Brazil (A, B) and Mexico (C, D), from 2011 to 2023.The figure consists of four horizontal bar charts showing the percentage change in years of life lost and years of potential productive life lost between 2011 and 2023 in Brazil and Mexico by cancer type and sex. Positive values indicate increases in burden, whereas negative values indicate decreases. In Brazil, for years of life lost, females experienced the highest increase in anal cancer (159.1%) and males in anal cancer (203.8%). For potential productive life lost, females saw the highest increase in anal cancer (151.7%) and males in anal cancer (138.6%). In Mexico, for years of life lost, females had the highest increase in oral cavity cancer (172.4%) and males in oropharyngeal cancer (74.6%). For potential productive life lost, females saw the highest increase in oral cavity cancer (228.6%) and males in oropharyngeal cancer (46.3%). Negative values indicate decreases in burden, including laryngeal cancer in Brazilian males (-20.0%) and Mexican females (-51.3%). HPV-attributable cancers showed heterogeneous changes across cancer types, countries and sexes.Four horizontal bar charts showing percent change in years of life lost (YLL) and potential productive life lost (YPPLL) from 2011 to 2023 in Brazil and Mexico by cancer type and sex.Note: (A) Brazil— Δ% YLL; (B) Brazil— Δ% YPPLL; (C) Mexico— Δ% YLL; (D) Mexico— Δ% YPPLL.HPV, human papillomavirus; Δ%, percentage change between 2011 and 2023, calculated as [(2023 value - 2011 value) / 2011 value] x 100; YLL, years of life lost; YPPLL, years of potential productive life lost. HPV‑attributable outcomes were derived by applying site‑specific attributable fractions to deaths at HPV‑associated cancer sites. Distribution of HPV-attributable years of life lost (YLL), by cancer type and sex, in Brazil (A, B) and Mexico (C, D), 2011 and 2023. Percentage change in years of life lost (YLL) and years of potential productive life lost (YPPLL) due to HPV-attributable cancers using national life tables, by cancer type and sex, in Brazil (A, B) and Mexico (C, D), from 2011 to 2023. Among men, HPV‑attributable cancer deaths increased from 884 in 2011 to 1,454 in 2023, with total YLL rising by 51.2% (Table 1). Head and neck cancers, predominantly oropharyngeal cancer, represented the largest share of male YLL in both study years, although the proportion of male YLL attributable to oropharyngeal cancer decreased from 47.6% in 2011 to 42.0% in 2023 (Table 1 ; Figure 1(B)). The largest relative increase in YLL among men was observed for anal cancer (+203.8%), followed by penile cancer (+54.8%). In contrast, laryngeal (+6.9%) and oral cavity (+6.6%) cancers showed only small increases in YLL between 2011 and 2023 (Table 1 ; Figure 2(A)). The median age at death from HPV‑attributable cancers increased from 60 y (IQR 51–71) in 2011 to 63 y (IQR 52–72) in 2023 (Table 1). YLL was higher in 2023 than in 2011 across younger adult age groups, particularly among individuals aged 30–49 y (Figure 3(A)). In 2011, the highest female YLL was observed at ages 40–49 y (41,192 YLL). Between 2011 and 2023, the largest relative increase in female YLL was observed among women at ages 30–39 (+60.7%), followed by those aged 40–49 y (+46.4%). Most YLL in both age groups were attributable to cervical cancer. Among men, YLL increased across all age groups, particularly among those aged 30–39 y (+52.4%) and ≥60 y (+97.3%), with anal, oropharyngeal, and penile cancers contributing substantially to YLL (Figure 3(A); Supplementary Table S5). Figure 3.HPV-attributable deaths and years of life lost (YLL), by sex and age group, in Brazil (A) and Mexico (B), 2011 and 2023.The figure consists of two combined bar and line charts showing HPV-attributable deaths and years of life lost (YLL) by sex and age group in Brazil (Image A) and Mexico (Image B), in 2011 and 2023. Bar represent the number of deaths (years) with categories <15, 15-29, 30-39, 40-49, 50-59, 60+, while lines represent the corresponding YLL. Results are presented separately for males and females. In Brazil, female YLL start to increase at 30-39 year and peaks at 40-49 year age groups and remained elevated in older age groups, while male YLL increased progressively with age and was the highest among individuals aged 60 years and older. Mexico shows similar pattern. Female YLL started to increase at 30-39 and peaks at 40-49 year age group and remained elevated in older age groups, whereas male YLL increased gradually with age.Two combined line and bar charts showing HPV-attributable deaths and years of life lost (YLL) by age group and sex in Brazil and Mexico.Note: (A) Brazil; (B) Mexico. Bars represent the number of HPV‑attributable deaths by sex, age group, and year, and lines represent the corresponding YLL. The left y-axis shows deaths (n), and the right y-axis shows YLL (years). HPV, human papillomavirus; YLL, years of life lost. HPV‑attributable outcomes were derived by applying site‑specific attributable fractions to deaths at HPV‑associated cancer sites. HPV-attributable deaths and years of life lost (YLL), by sex and age group, in Brazil (A) and Mexico (B), 2011 and 2023. Across both sexes, reflecting the predominance of deaths among women, AYLL remained stable at 26 y per HPV-attributable cancer death in both study years. AYLL values were consistently higher among women (27 y per death in both study years), particularly for cervical cancer (28 y per death in both study years). Among men, AYLL declined slightly from 21 to 19 y per death, with the highest values for oropharyngeal cancer: 22 y per death in 2011 and 20 y per death in 2023 (Table 2).Table 2.Average years of life lost per HPV-attributable cancer death by cancer type and sex in Brazil and Mexico, 2011 and 2023.SexCancer typeBrazilMexico2011202320112023FemaleAnal20202118Cervical28282526Laryngeal19191717Oral cavity17171517Oropharyngeal21201718Vaginal18181618Vulvar22202220Head and neck20191718Overall HPV-attributable27272526MaleAnal21192320Laryngeal20171616Oral cavity21181817Oropharyngeal22201918Penile19182119Head and neck21191717Overall HPV-attributable21191918Both sexesAnal21192219Laryngeal20181716Oral cavity20181717Oropharyngeal21201918Head and neck21191717Overall HPV-attributable26262425AYLL was calculated as HPV-attributable YLL divided by HPV-attributable deaths. Head and neck cancers include oral cavity, laryngeal, and oropharyngeal cancers. HPV, human papillomavirus; AYLL, average years of life lost; YLL, years of life lost. Table 2.Average years of life lost per HPV-attributable cancer death by cancer type and sex in Brazil and Mexico, 2011 and 2023.SexCancer typeBrazilMexico2011202320112023FemaleAnal20202118Cervical28282526Laryngeal19191717Oral cavity17171517Oropharyngeal21201718Vaginal18181618Vulvar22202220Head and neck20191718Overall HPV-attributable27272526MaleAnal21192320Laryngeal20171616Oral cavity21181817Oropharyngeal22201918Penile19182119Head and neck21191717Overall HPV-attributable21191918Both sexesAnal21192219Laryngeal20181716Oral cavity20181717Oropharyngeal21201918Head and neck21191717Overall HPV-attributable26262425AYLL was calculated as HPV-attributable YLL divided by HPV-attributable deaths. Head and neck cancers include oral cavity, laryngeal, and oropharyngeal cancers. HPV, human papillomavirus; AYLL, average years of life lost; YLL, years of life lost. Average years of life lost per HPV-attributable cancer death by cancer type and sex in Brazil and Mexico, 2011 and 2023. AYLL was calculated as HPV-attributable YLL divided by HPV-attributable deaths. Head and neck cancers include oral cavity, laryngeal, and oropharyngeal cancers. HPV, human papillomavirus; AYLL, average years of life lost; YLL, years of life lost. In line with the overall increase in YLL, YPPLL increased from 67,703 y in 2011 to 97,404 y in 2023 (+43.9%) (Table 1). Reductions in YPPLL were observed for laryngeal cancer in both women (−9.1%) and men (−20.0%), as well as for oral cavity cancer in men (−16.2%) (Table 1; Figure 2(B)). By age group, YPPLL increased most markedly among individuals aged 30–39 y (+60.0%) and 40–49 y (+44.2%), with cervical cancer contributing most YPPLL among women and anal, oropharyngeal, and penile cancers among men (Supplementary Table S5). For HPV‑attributable cancers in Brazil, CMRs increased from 3.3 to 4.4 per 100,000 in both sexes combined between 2011 and 2023. Differences in ASMRs were smaller: rates increased from 5.5 to 5.9 per 100,000 among women and from 1.0 to 1.2 per 100,000 among men (Supplementary Table S4). Anal cancer showed the largest increases in ASMR, from 0.1 to 0.3 per 100,000 among men and from 0.2 to 0.3 per 100,000 among women. Smaller ASMR increases were observed for penile cancer and for male oropharyngeal cancer. In contrast, ASMR for laryngeal cancer decreased in men and remained low and stable in women. Mexico Across both sexes in Mexico, the absolute number of HPV-attributable cancer deaths increased from 4,303 in 2011 to 4,997 in 2023, while total YLL rose by 21.4% (Table 3; Supplementary Table S6).Table 3.Life-table based years of life lost and years of potential productive life lost due to HPV-attributable cancers in Mexico, by cancer type and sex, 2011 and 2023.Cancer type20112023Δ% (2011–2023)DeathsAge at deathYLLYPPLLDeathsAge at deathYLLYPPLLYLLYPPLLn (%)median (P25-P75)years (%)years (%)n (%)median (P25-P75)years (%)years (%)%%Female Anal41 (1.0)66 (56–77)853 (0.9)299 (0.8)46 (1.0)68 (56–76)838 (0.7)190 (0.4)−1.8−36.5Cervical3,925 (96.8)56 (45–69)97,516 (97.6)38,662 (98.2)4,500 (96.2)56 (44–69)118,028 (97.3)49,443 (98.4)21.027.9Laryngeal18 (0.4)66 (57–76)306 (0.3)76 (0.2)10 (0.2)68 (60–78)174 (0.1)37 (0.1)−43.1−51.3Oral cavity5 (0.1)74 (62–83)76 (0.1)14 (0.0)12 (0.3)73 (60–83)207 (0.2)46 (0.1)172.4228.6Oropharyngeal8 (0.2)67 (54–78)139 (0.1)39 (0.1)14 (0.3)67 (58–76)255 (0.2)61 (0.1)83.556.4Vaginal36 (0.9)69 (59–82)577 (0.6)114 (0.3)56 (1.2)73 (60–81)1,021 (0.8)248 (0.5)76.9117.5Vulvar22 (0.5)73 (62–83)476 (0.5)173 (0.4)39 (0.8)75 (65–83)775 (0.6)227 (0.5)62.831.2Head and neck31 (0.8)68 (57–79)521 (0.5)129 (0.3)36 (0.8)69 (59–79)636 (0.5)144 (0.3)22.111.6Overall HPV-attributable4,055 (100.0)60 (48–72)99,943 (100.0)39,377 (100.0)4,677 (100.0)60 (47–73)121,298 (100.0)50,252 (100.0)21.427.6MaleAnal27 (10.9)62 (50–74)619 (13.1)272 (18.8)41 (12.8)65 (55–75)822 (14.4)296 (20.0)32.88.8Laryngeal99 (39.9)62 (54–71)1,630 (34.6)319 (22.1)78 (24.4)66 (59–73)1,226 (21.5)202 (13.6)−24.8−36.7Oral cavity10 (4.0)61 (52–70)176 (3.7)61 (4.2)17 (5.3)65 (57–72)284 (5.0)74 (5.0)61.421.3Oropharyngeal32 (12.9)59 (52–67)602 (12.8)149 (10.3)59 (18.4)62 (55–69)1,051 (18.4)218 (14.7)74.646.3Penile80 (32.3)66 (53–77)1,688 (35.8)642 (44.5)125 (39.1)66 (55–76)2,325 (40.7)693 (46.7)37.77.9Head and neck141 (56.9)61 (53–70)2,408 (51.1)529 (36.7)154 (48.1)64 (57–72)2,561 (44.9)494 (33.3)6.4−6.6Overall HPV-attributable248 (100.0)61 (53–70)4,715 (100.0)1,443 (100.0)320 (100.0)64 (57–72)5,708 (100.0)1,483 (100.0)21.12.8Both sexesOverall HPV-attributable4,303 (100.0)60 (51–71)104,658 (100.0)40,820 (100.0)4,997 (100.0)63 (52–72)127,006 (100.0)51,735 (100.0)21.426.7HPV, human papillomavirus; YLL, years of life lost; YPPLL, years of potential productive life lost. Head and neck cancers represent the aggregate of oral cavity, laryngeal, and oropharyngeal cancers and are not an additional mutually exclusive category. Δ%: percentage change from 2011 to 2023, calculated as [(2023 value − 2011 value) / 2011 value] × 100. HPV-attributable deaths were estimated by applying site-specific attributable fractions to total deaths and rounding to the nearest whole number (≥0.5, rounded up; <0.5, rounded down). Table 3.Life-table based years of life lost and years of potential productive life lost due to HPV-attributable cancers in Mexico, by cancer type and sex, 2011 and 2023.Cancer type20112023Δ% (2011–2023)DeathsAge at deathYLLYPPLLDeathsAge at deathYLLYPPLLYLLYPPLLn (%)median (P25-P75)years (%)years (%)n (%)median (P25-P75)years (%)years (%)%%Female Anal41 (1.0)66 (56–77)853 (0.9)299 (0.8)46 (1.0)68 (56–76)838 (0.7)190 (0.4)−1.8−36.5Cervical3,925 (96.8)56 (45–69)97,516 (97.6)38,662 (98.2)4,500 (96.2)56 (44–69)118,028 (97.3)49,443 (98.4)21.027.9Laryngeal18 (0.4)66 (57–76)306 (0.3)76 (0.2)10 (0.2)68 (60–78)174 (0.1)37 (0.1)−43.1−51.3Oral cavity5 (0.1)74 (62–83)76 (0.1)14 (0.0)12 (0.3)73 (60–83)207 (0.2)46 (0.1)172.4228.6Oropharyngeal8 (0.2)67 (54–78)139 (0.1)39 (0.1)14 (0.3)67 (58–76)255 (0.2)61 (0.1)83.556.4Vaginal36 (0.9)69 (59–82)577 (0.6)114 (0.3)56 (1.2)73 (60–81)1,021 (0.8)248 (0.5)76.9117.5Vulvar22 (0.5)73 (62–83)476 (0.5)173 (0.4)39 (0.8)75 (65–83)775 (0.6)227 (0.5)62.831.2Head and neck31 (0.8)68 (57–79)521 (0.5)129 (0.3)36 (0.8)69 (59–79)636 (0.5)144 (0.3)22.111.6Overall HPV-attributable4,055 (100.0)60 (48–72)99,943 (100.0)39,377 (100.0)4,677 (100.0)60 (47–73)121,298 (100.0)50,252 (100.0)21.427.6MaleAnal27 (10.9)62 (50–74)619 (13.1)272 (18.8)41 (12.8)65 (55–75)822 (14.4)296 (20.0)32.88.8Laryngeal99 (39.9)62 (54–71)1,630 (34.6)319 (22.1)78 (24.4)66 (59–73)1,226 (21.5)202 (13.6)−24.8−36.7Oral cavity10 (4.0)61 (52–70)176 (3.7)61 (4.2)17 (5.3)65 (57–72)284 (5.0)74 (5.0)61.421.3Oropharyngeal32 (12.9)59 (52–67)602 (12.8)149 (10.3)59 (18.4)62 (55–69)1,051 (18.4)218 (14.7)74.646.3Penile80 (32.3)66 (53–77)1,688 (35.8)642 (44.5)125 (39.1)66 (55–76)2,325 (40.7)693 (46.7)37.77.9Head and neck141 (56.9)61 (53–70)2,408 (51.1)529 (36.7)154 (48.1)64 (57–72)2,561 (44.9)494 (33.3)6.4−6.6Overall HPV-attributable248 (100.0)61 (53–70)4,715 (100.0)1,443 (100.0)320 (100.0)64 (57–72)5,708 (100.0)1,483 (100.0)21.12.8Both sexesOverall HPV-attributable4,303 (100.0)60 (51–71)104,658 (100.0)40,820 (100.0)4,997 (100.0)63 (52–72)127,006 (100.0)51,735 (100.0)21.426.7HPV, human papillomavirus; YLL, years of life lost; YPPLL, years of potential productive life lost. Head and neck cancers represent the aggregate of oral cavity, laryngeal, and oropharyngeal cancers and are not an additional mutually exclusive category. Δ%: percentage change from 2011 to 2023, calculated as [(2023 value − 2011 value) / 2011 value] × 100. HPV-attributable deaths were estimated by applying site-specific attributable fractions to total deaths and rounding to the nearest whole number (≥0.5, rounded up; <0.5, rounded down). Life-table based years of life lost and years of potential productive life lost due to HPV-attributable cancers in Mexico, by cancer type and sex, 2011 and 2023. HPV, human papillomavirus; YLL, years of life lost; YPPLL, years of potential productive life lost. Head and neck cancers represent the aggregate of oral cavity, laryngeal, and oropharyngeal cancers and are not an additional mutually exclusive category. Δ%: percentage change from 2011 to 2023, calculated as [(2023 value − 2011 value) / 2011 value] × 100. HPV-attributable deaths were estimated by applying site-specific attributable fractions to total deaths and rounding to the nearest whole number (≥0.5, rounded up; <0.5, rounded down). Among women, HPV-attributable deaths increased from 4,055 in 2011 to 4,677 in 2023, with a corresponding 21.4% increase in YLL (Table 3). Cervical cancer represented approximately 97% of YLL in both years (Figure 1(C)). Relative increases in YLL were observed for oral cavity (+172.4%), oropharyngeal (+83.5%), vaginal (+76.9%), and vulvar cancers (+62.8%). In contrast, YLL decreased for laryngeal cancer (−43.1%) and anal cancer (−1.8%) (Figure 2(C)). Among men, HPV-attributable deaths rose from 248 in 2011 to 320 in 2023, with YLL increasing by 21.1% (Table 3). Penile cancer was the leading individual contributor to male YLL in both years, whereas the combined YLL from head and neck cancers (oral cavity, laryngeal, and oropharyngeal) exceeded that from penile cancer in both years (Figure 1(D); Table 3). The largest relative increases in male YLL were observed for oropharyngeal (+74.6%), oral cavity (+61.4%), penile (+37.7%), and anal cancers (+32.8%), whereas laryngeal cancer declined (−24.8%) (Table 3; Figure 2(C)). The median age at death from HPV‑attributable cancers increased slightly from 60 y (IQR 51–71) in 2011 to 63 y (IQR 52–72) in 2023 (Table 3). Among women, YLL rose across all adult age groups, with the largest relative increase observed among those aged 30–39 y (+59.5%), followed by those aged 40–49 y (+17.3%) and 50–59 y (+16.9%). Cervical cancer remained the main contributor to YLL across all female age groups, whereas non‑cervical cancers contributed a greater proportion of YLL at older ages. Among men, YLL declined at ages 30–39 y (−34.5%) and 40–49 y (−11.4%) but increased at ages 50–59 y (+22.6%) and ≥60 y (+39.7%) (Figure 3(B); Supplementary Table S7). Across both years, AYLL ranged from 24 to 25 y per HPV-attributable cancer death. Women consistently had higher AYLL values, with cervical cancer reaching 26 y of life lost per death in 2023. Among men, AYLL ranged from 18 to 19 y per death, with the highest values observed for anal and penile cancers: 20 and 19 y per death, respectively (Table 2). Overall YPPLL increased from 40,820 y in 2011 to 51,735 y in 2023 (+26.7%) (Table 3). Among women, cervical cancer accounted for 98.4% of female YPPLL in 2023 (49,443 y). Among men, YPPLL increased modestly (+2.8%), as increases in oropharyngeal (+46.3%) and oral cavity cancers (+21.3%) were largely offset by a sharp decline in laryngeal cancer (−36.7%) (Table 3; Figure 2(D)). By age group, the largest relative increases in YPPLL among women were observed in the age groups 30–39 and 40–49 y (+60.6% and +18.0%, respectively), whereas among men, YPPLL declined at ages 30–39 y and 40–49 y and increased mainly at ages 50–59 y (Supplementary Table S7). For both sexes combined in Mexico, the HPV‑attributable CMR was 3.7 per 100,000 in 2011 and 3.8 per 100,000 in 2023, while the ASMR decreased from 4.6 to 3.8 per 100,000 (Supplementary Table S6). Among women, the CMR increased from 6.8 to 7.0 per 100,000, while the ASMR decreased from 8.1 to 6.6 per 100,000. Site‑specific ASMRs among women showed the largest declines in laryngeal, anal, and cervical cancers, whereas a small increase was observed for oral cavity cancer. Among men, the CMR increased from 0.4 to 0.5 per 100,000, while the ASMR decreased from 0.6 to 0.5 per 100,000. Site‑specific ASMRs among men increased for anal, penile, oral cavity, and oropharyngeal cancers, while laryngeal cancer showed the largest decrease. Sensitivity analysis Sensitivity analysis using WHO GHE standard life tables yielded higher YLL estimates than the primary analysis based on national life tables because of the longer life expectancy assumptions. However, the relative distribution of YLL by cancer type and sex, as well as the percentage changes between 2011 and 2023, remained consistent across methods. In 2023, WHO GHE estimates for Brazil were 270,040 YLL among women and 40,128 YLL among men, values 23.7% and 46.0% higher, respectively, than the corresponding national life table estimates. In Mexico, WHO GHE estimates were 155,371 YLL among women and 8,018 YLL among men, values 28.1% and 40.5% higher, respectively, than the corresponding national lifetable estimates. These differences arise because the WHO GHE life tables assume higher remaining life expectancy than the national life tables used in the primary analysis, which incorporate country-specific mortality patterns. For instance, at age 40, remaining life expectancy is greater under the WHO GHE life tables (50.4 y) than under the Brazilian (41.9 y for women, 37.2 y for men) or Mexican (40.7 y for women, 36.9 y for men) national life tables (Supplementary Tables S3 , S8, and S9). Discussion Our study shows that HPV-attributable cancers are a major source of premature mortality in Brazil and Mexico. In both countries, deaths, YLL, and YPPLL were higher in 2023 than in 2011, with cervical cancer remaining the predominant contributor to HPV-attributable mortality. Higher YLL in 2023 also reflected premature deaths from several other HPV-attributable cancers, particularly oropharyngeal, anal, penile, vaginal, and vulvar cancers. Although most deaths occurred at older ages, a considerable proportion of YLL and YPPLL accumulated during working ages, highlighting the broader societal impact of HPV-attributable cancers. National population projections provide important context for interpreting the absolute burden observed in the two study years.25,26 Higher CMRs, accompanied by modest increases in ASMRs in Brazil and declining ASMRs in Mexico, were consistent with demographic change, although the contribution of population growth and aging was not formally quantified. These ASMR patterns do not necessarily imply lower health-system needs, as the absolute number of HPV-attributable deaths may signal a larger patient population requiring diagnostic evaluation, oncology treatment, and supportive care throughout the disease course. YLL and YPPLL therefore complement mortality rates by capturing the timing and societal impact of premature deaths. Cervical cancer accounted for 92.2% of female YLL in Brazil and 97.3% in Mexico in 2023. This predominance aligns with regional projections indicating that, without accelerated intervention, this cancer will remain a major public health challenge in Latin America.33,34 It is also consistent with Brazilian projections suggesting that population growth and aging may increase the absolute number of deaths even as age-standardized rates decline.35 Importantly, in our study, the concentration of YLL and YPPLL at relatively young adult ages underscores the social and economic consequences of preventable deaths during working and reproductive years. Previous estimates of productivity losses from premature cervical cancer deaths in Latin America exceeded US$4 billion, with Brazil and Mexico each accounting for approximately US$1 billion among working-age women.13 Beyond cervical cancer, our results demonstrate a substantial multisite HPV‑attributable cancer burden in both countries. Anal cancer was particularly notable: YLL was substantially higher in 2023 than in 2011 among both women and men in Brazil, whereas the difference between the two years was smaller in Mexico and concentrated among men. Increasing anal cancer incidence and mortality have been reported in studies from high-income countries,36–39 and risk is markedly elevated among key populations, including men who have sex with men and individuals living with HIV.39–41 These observations support sustained HPV vaccination in both sexes, complemented by risk-based follow-up, identification and treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer,40 and timely diagnosis and treatment of invasive disease. Penile and head and neck cancers, particularly oropharyngeal cancer, contributed substantially to the HPV-attributable burden among men in both countries. In Brazil, oropharyngeal cancer remained one of the leading HPV-attributable sites in men, while YLL from penile cancer was more than 50% higher in 2023 than in 2011. In Mexico, penile cancer was the largest individual contributor to male YLL, although the combined contribution of head and neck cancers exceeded that of penile cancer in both years. Within the head and neck category, YLL from oropharyngeal and oral cavity cancers was higher in 2023 than in 2011, whereas YLL from laryngeal cancer was lower. These contrasting patterns highlight the importance of disaggregating head and neck cancers by anatomical site. Consistent with previous evidence from Latin America, head and neck cancer burden and associated YPPLL were concentrated among men.13 Although less common than cervical or head and neck cancers, vaginal and vulvar cancers contributed meaningfully to HPV-attributable premature mortality among adult women. In Brazil, YLL was higher in 2023 than in 2011, particularly for vaginal cancer among women aged 30–49 y and for vulvar cancer among those aged 30–59 y and ≥60 y. In Mexico, the difference between the two study years was particularly marked for vaginal cancer across several adult age groups. Although the reasons for these differences cannot be determined from the present analysis, the findings support integrating these sites into HPV prevention and cancer-control strategies through sustained HPV vaccination and improved access to early diagnosis and specialized treatment in both countries.7,42 A key strength of our study is the use of national mortality data from established death-registration systems, combined with country-specific and WHO GHE life tables and region- and cancer-specific AFs. By estimating deaths, YLL, and YPPLL, the study provides a policy-relevant perspective on premature mortality that complements age-standardized rates and helps distinguish differences in absolute burden between the two study years from differences in underlying mortality risk. However, several limitations exist. First, we applied fixed AFs to both study years and, except for vulvar cancer, across age groups. Although we prioritized regionally relevant HPV DNA/p16INK4a-based data, this approach may not capture temporal variation in HPV attribution. This limitation may be particularly relevant to head and neck cancers, whose etiology is also influenced by tobacco use, alcohol consumption, and sexual behaviors.3,43,44 Second, mortality data remain subject to cause-of-death and cancer-site misclassification. Third, the comparison of 2011 and 2023 cannot establish a continuous trajectory or support formal trend analysis. Finally, YPPLL estimate potential productive years lost based on age at death and a working-age cutoff, without incorporating employment status or labor-market participation. Future studies should evaluate annual trends, subnational heterogeneity, and epidemiological drivers of HPV-attributable burden. As part of a comprehensive public health response, HPV vaccination remains the cornerstone of primary prevention. However, because HPV-related cancers develop over decades, the mortality burden observed in 2011 and 2023 largely reflects cohorts that were not protected through adolescent vaccination programs. While early population‑level benefits of vaccination are beginning to emerge in Brazil,45–47 achieving near- and medium-term reductions in mortality will require strengthening the entire prevention and care cascade. This integrated approach aligns with the WHO cervical cancer elimination strategy and its 90–70-90 targets, while HPV vaccination also supports the broader prevention of HPV-attributable cancers across multiple sites and in both sexes.4 In conclusion, our findings reveal a persistent, substantial, and largely preventable burden of premature mortality from HPV-attributable cancers in Brazil and Mexico. Although ASMRs remained stable or changed only modestly in Brazil and declined in Mexico, absolute deaths, YLL, and YPPLL were higher in 2023 than in 2011 in the context of population growth and aging. These higher absolute numbers may translate into greater health-system needs for timely diagnosis, specialized oncology treatment, and supportive care throughout the disease course. Our data also demonstrate that the burden extends across multiple anatomical sites, with differences between the two study years. Among women, cervical cancer remained the leading contributor, although higher YLL was observed for anal, vulvar, and vaginal cancers. Among men, the burden involved multiple anatomical sites, with substantial contributions from head and neck cancers and higher YLL from oropharyngeal, anal, and penile cancers. These findings support regional action plans to strengthen HPV prevention and comprehensive multisite cancer control for both sexes in Brazil and Mexico. Supplementary Material Supplementary_material_clean_V3 (1).docx